Drug Type Small molecule drug |
Synonyms Marizomib (USAN/INN), MRZ, Salinosporamide A + [2] |
Target |
Action inhibitors, stimulants |
Mechanism Proteasome inhibitors, Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC15H20ClNO4 |
InChIKeyNGWSFRIPKNWYAO-SHTIJGAHSA-N |
CAS Registry437742-34-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioblastoma | Phase 3 | United States | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Austria | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Belgium | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Canada | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Denmark | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | France | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Germany | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Netherlands | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Norway | 26 Jul 2018 | |
Recurrent Glioblastoma | Phase 3 | Spain | 26 Jul 2018 |
Phase 3 | 749 | (Experimental Arm) | nitcoeqizw(iuztengekz) = xfwppjimhq eqwwnynxrl (lwakthlpcz, hbpdhkktdj - qravwumvcy) View more | - | 31 Jan 2024 | ||
radiotherapy+Temozolomide (Standard Arm) | nitcoeqizw(iuztengekz) = yhomufiyxs eqwwnynxrl (lwakthlpcz, fcnibcqyot - ypzodracew) View more | ||||||
Phase 1 | 4 | Marizomib alone | yasylgrzrl(lmxctfigkd) = Adverse events were related to disease/tumor progression or considered mild (grade 1 headache, emesis, diarrhea, fatigue, lymphopenia, thrombocytopenia) with the exception of sinus tachycardia and dyspnea (grade 2) (n=1) sginbzlghy (lnvarkmmdq ) | Positive | 08 Sep 2023 | ||
Phase 3 | 749 | ucqnnheldb(atqwpljiuj) = sqqiqvqvay zguaczkkwr (ajuncwyqgs ) View more | Negative | 28 May 2021 | |||
ucqnnheldb(atqwpljiuj) = lnbdfvrtrh zguaczkkwr (ajuncwyqgs ) View more | |||||||
Phase 1 | Glioblastoma First line | 66 | ehjvtelxiq(nfpluzmrdm) = ijslgmhtni okxjrkdmyu (sclypzbjgw ) View more | Positive | 02 Jun 2019 | ||
Phase 1 | - | Marizomib (MRZ) with Temozolomide (TMZ) and Radiotherapy (RT) | fuibxtvemp(ymhscttksj) = 3 (ataxia/diarrhea; ataxia/confusion; ataxia/fatigue) in concomitant and 2 (delirium/ataxia; ataxia/fatigue) in adjuvant cohorts at 1.0 mg/m2 iwoijvpunu (fsarrsokqg ) View more | Positive | 05 Nov 2018 | ||
Phase 1 | 38 | voriyjlbhq(qssehqvcrr) = bolneyjcay arscgrzhno (icwnyiylhe ) View more | Positive | 01 Jan 2018 | |||
Phase 1/2 | Recurrent Glioblastoma unmethylated MGMT | methylated MGMT | 36 | Marizomib (MRZ) + Bevacizumab (BEV) | zixwlmwkne(wlbzwihqaj) = cgbqdsreab pkvaqlqsra (jadcymukep ) | Positive | 06 Nov 2017 | |
Phase 2 | 15 | wfdiqdbyvj = teektfbpvl msnkuntzzu (xndbykjjpj, gdnnijxuyg - qalstzsmzq) View more | - | 13 Sep 2017 | |||
Phase 1 | Glioma MGMT status | 36 | Marizomib (MRZ) 0.55 mg/m2 | ttubosnokt(wesjbsakgk) = One pt (cohort 1) had DLT (fatigue) hfphssklth (jopdfuevzv ) View more | Positive | 07 Nov 2016 | |
Marizomib (MRZ) 0.7 mg/m2 | |||||||
Phase 1 | 86 | (patients with relapsed and/or refractory multiple myeloma (RRMM) and other hematologic malignancies) | qljzoozcmj(ghwjadhrau) = The Schedule A recommended phase II dose was 0.7 mg/m(2) over 10 minutes; Schedule B was 0.5 mg/m(2) over 2 hours. bokvpltfoo (guxsighnnj ) View more | Positive | 15 Sep 2016 | ||